Skip to content
Open access

Astragaloside IV attenuates hypoxia-reoxygenation-induced endothelial senescence and vascular inflammation by modulating the NOTCH1/VCAM-1 axis

Aug 2026 · Frontiers in Aging Neuroscience · Vol 18 · 0 citations · 39 references
Medicine

TL;DR

The data suggest that AS-IV does not merely inhibit Notch1 but acts by modulating its signaling toward a protective equilibrium, thereby attenuating endothelial senescence and inflammation associated with the restoration of Notch1/VCAM-1 signaling balance.

Abstract

Objective Alzheimer's disease (AD) progression involves cerebral microvascular endothelial cell senescence induced by brain hypoperfusion, which contributes to blood-brain barrier (BBB) dysfunction. While Notch1 signaling is known to exacerbate endothelial senescence and neuroinflammation via vascular cell adhesion molecule-1 (VCAM-1), the mechanism by which it mediates hypoxia-induced endothelial aging in AD remains unclear. Furthermore, although Astragaloside IV (AS-IV) has been shown to alleviate cerebral hypoperfusion in AD, whether it acts by directly modulating the Notch1/VCAM-1 axis is unknown. This study aimed to determine whether AS-IV mitigates endothelial senescence and AD pathology by modulating the Notch1/VCAM-1 pathway. Methods Transcriptomic analysis of AD patient data and network pharmacology identified NOTCH1 as a key target. Molecular docking and 100-ns molecular dynamics simulations (using Desmond) characterized AS-IV–Notch1 interactions. Human brain microvascular endothelial cells (HBMECs) were subjected to hypoxia-reoxygenation (HR) to model AD-associated hypoperfusion. Cells were treated with AS-IV (25, 50, or 100 μM) or N-acetylcysteine (NAC) as a positive antioxidant control. Notch1 signaling was experimentally modulated using a recombinant decoy receptor to simulate signaling blockade, creating a contrast with HR-induced overactivation. Assessments included CCK-8 assays, MDA and ROS detection, qPCR, and Western blotting. Results NOTCH1 expression was upregulated in AD patients. Molecular docking and dynamics simulations predicted a stable binding mode between AS-IV and Notch1. HR exposure significantly increased oxidative stress and upregulated senescence markers (p16, p21, and p53), proinflammatory senescence-associated secretory phenotype (SASP) factors (IL-6, IL-1β, and TNF-α), and Notch1/VCAM-1 expression. Conversely, AS-IV treatment improved cell viability, reduced oxidative stress (with efficacy comparable to NAC), and downregulated Notch1/VCAM-1, senescence, and SASP markers. Notably, perturbing Notch signaling, either through HR-induced overactivation or decoy receptor-mediated blockade, exacerbated the senescent phenotype. Importantly, AS-IV co-treatment effectively rescued cellular damage induced by both forms of Notch pathway dysregulation. Conclusion AS-IV alleviates HR-induced endothelial senescence by modulating the Notch1/VCAM-1 axis. Our data suggest that AS-IV does not merely inhibit Notch1 but acts by modulating its signaling toward a protective equilibrium, thereby attenuating endothelial senescence and inflammation associated with the restoration of Notch1/VCAM-1 signaling balance. These findings highlight the potential of AS-IV as a therapeutic candidate for AD vascular pathology.

Read PDF

Similar papers

Open access Sep 2026

Andrographolide Promotes Post-Ischemic Endothelial Angiogenic Activity via IL-10-Mediated M2-Like Microglia–Endothelial Crosstalk Involving Endothelial VEGFR2 Upregulation

The results show that andrographolide promotes post-stroke vascular repair, at least in part, by regulating the interaction between brain immune cells and vascular cells, offering new insight into how this compound may support brain repair after ischemic stroke.

Hong-Fei Li, Hai-Rong Xiang, Xin-Yu Li et al. · 0 citations
Open access Aug 2026

Paeoniflorin Alleviates Oxygen–Glucose Deprivation/Reoxygenation Injury by Mediating Crosstalk Between Neurons and Endothelial Cells Through the VEGF/PI3K-AKT/mTOR Pathway

Paeoniflorin alleviated CIRI by directly protecting neurons and indirectly modulating neuron–endothelial crosstalk through VEGF/PI3K-AKT/mTOR activation, supporting its multi-target therapeutic potential.

Zi-Shuo Xu, Hong Luo, Yi-Ming Zhao et al. · 0 citations
Aug 2026

PDCD4/PPARα axis regulates oxidative stress-mediated microvascular endothelial injury in myocardial ischemia-reperfusion.

Cardiac microvascular endothelial cell (CMEC) injury is a primary driver of microvascular obstruction and the no-reflow phenomenon during myocardial ischemia/reperfusion (I/R). While Programmed Cell Death 4 (PDCD4) is known to exacerbate cardiovascular diseases, its precise role and regulatory mechanisms in CMEC barrie...

Midilibieke Hasidaer, Yu-Chun Yang, Z. Bao et al. · 0 citations
Sep 2026

Quercetin protects brain microvascular endothelial cells against hypoxia/reoxygenation-induced injury and ferroptosis by targeting the TCF3/ALOX15 axis: Implications for cerebral small vessel disease.

BACKGROUND Cerebral small vessel disease (CSVD) is a leading cause of vascular cognitive impairment and stroke. Quercetin is a natural flavonoid with neuroprotective effects in various cerebrovascular disorders. However, its specific molecular targets and mechanisms in CSVD remain elusive. METHODS Bioinformatic analy...

Meng-Jie Cao, Ying-Xiao Ji, Bin Zhang et al. · 0 citations
Aug 2026

The role and mechanism of rosiglitazone in endothelial-to-mesenchymal transition in pulmonary hypertension.

OBJECTIVE Pulmonary hypertension (PH) involves endothelial-to-mesenchymal transition (EndMT) in vascular remodeling. Rosiglitazone (RSG), a peroxisome proliferator-activated receptor gamma agonist, alleviates PH, but its direct effect on EndMT is unclear. The study explores RSG's role and mechanism in inhibiting EndMT....

Ao-Xue Yuan, Yaqian Bai, Yuanhang Jiang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.